Wapnick Pamela 4

What Happened

• Pamela Wapnick, Chief Financial Officer of Metagenomi Therapeutics (MGX), had 2,884 shares of common stock sold on June 5, 2026 at $1.30 per share, generating $3,746 in proceeds. The sale was reported on Form 4 filed June 10, 2026.
• This was a sale resulting from tax withholding on vested restricted stock units (RSUs), not an independent, volitional sell decision by the insider.

Key Details

• Transaction date: June 5, 2026; Price: $1.30 per share; Shares sold: 2,884; Proceeds: $3,746.
• Footnote: Shares were “automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations” for RSUs granted April 1, 2024 and April 1, 2025 — not a discretionary trade (F1).
• Shares owned after the transaction: not specified in the provided filing details.
• Filing: Form 4 filed on June 10, 2026 (5 calendar days after the trade); Form 4s are typically required within 2 business days, so this filing appears later than the usual reporting window.

Context

• Sales to cover tax withholding are common when RSUs vest and generally do not signal the insider’s view on the company’s stock. The transaction value here ($3.7k) is small and likely administrative in nature rather than an investment decision.